The U.S. Food and Drug Administration (FDA) said on Friday it approved Novartis AG's treatment in combination with hormone therapy fulvestrant for postmenopausal women, as well as men, with a form of advanced breast cancer.
from Reuters: Health News https://reut.rs/2MhNBcm
via
IFTTT
0 comments:
Post a Comment